A judge declined to dismiss Arkansas’ case against Johnson & Johnson, leaving it to face trial in March 2010 on claims that it violated labeling and marketing regulations in connection with its anti-psychotic drug Risperdal.

Johnson & Johnson allegedly marketed Risperdal for unapproved uses, including dementia and mood and anxiety disorders and downplayed the drug’s risks, failing to adequately disclose such risks in the drug’s labeling materials.

Johnson & Johnson lost a related case in a Louisiana jury trial last year and another before a South Carolina judge in June.  Johnson & Johnson was ordered to pay $258 million and $327 million, respectively.  They are contesting both cases.

Read the entire article, “J&J Must Face 2012 Arkansas Trial Over Risperdal Marketing”